Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 


PDE inhibitor
BML-EI117-0100 100 mg 153.00 USD
BML-EI117-1000 1 g 544.00 USD
Do you need bulk/larger quantities?
Replaces Prod. #: ALX-270-118

Selective, potent cAMP-specific phosphodiesterase inhibitor (PDE IV, IC50=2µM). Inhibits superoxide generation and platelet aggregation stimulated by arachidonic acid. Also inhibits fMLP-induced neutrophil adhesion to vascular endothelial cells.

Product Details

Alternative Name:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone
Purity:≥99% (TLC)
Appearance:White to off-white solid.
Solubility:Soluble in 100% ethanol (40mg/ml) or DMSO (200 mg/ml); insoluble in water.
Shipping:Ambient Temperature
Long Term Storage:Ambient
Use/Stability:Stable for at least 1 year after receipt when stored at +20°C. Solutions are stable for up to 3 months when stored at -20°C.
Regulatory Status:RUO - Research Use Only
Please mouse over

Product Literature References

Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators: C.K. Derian, et al.; J. Immunol. 154, 308 (1995), Abstract;
A cell culture model of the blood-brain barrier: L.L. Rubin, et al.; J. Cell. Biol. 115, 1725 (1991), Abstract;
Differential effects of Ro 20-1724 and isobutylmethylxanthine on the basal force of contraction and beta-adrenoceptor-mediated response in the rat ventricular myocardium: Y. Katano & M. Endoh; BBRC 167, 123 (1990), Abstract;
The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors: M.L. Reeves, et al.; Biochem. J. 241, 535 (1987), Abstract;
Receptor-specific threshold effects of cyclic AMP are involved in the regulation of enzyme release and superoxide production from human neutrophils: P.M. Lad, et al.; Biochim. Biophys. Acta 846, 286 (1985), Abstract;
Evidence for mediation of acetyl glyceryl ether phosphorylcholine stimulation of adenosine 3',5'-(cyclic)monophosphate levels in human polymorphonuclear leukocytes by leukotriene B4: N.K. Hopkins, et al.; Biochim. Biophys. Acta 763, 276 (1983), Abstract;
Tissue and substrate specificity of inhibition by alkoxy-aryl-lactams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases relationship to pharmacological activity: C. Lugnier, et al.; BBRC 113, 954 (1983), Abstract;
Selective inhibition of cyclic AMP and cyclic GMP phosphodiesterases of cardiac nuclear fraction: G.S. Ahluwalia & A.R. Rhoads; Biochem. Pharmacol. 31, 665 (1982), Abstract;
Effects of antiallergic agents, compound 48/80, and some reference inhibitors on the activity of partially purified human lung tissue adenosine cyclic 3',5'-monophosphate and guanosine cyclic 3',5'- monophosphate phosphodiesterases: H. Bergstrand, et al.; Mol. Pharmacol. 13, 38 (1977), Abstract;
Structure-activity relationships for inhibitors of phosphodiesterase from erythrocytes and other tissues: H. Sheppard, et al.; Adv. Cycl. Nucl. Res. 1, 103 (1972), Abstract;